Identification and Structure− Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
N Jain, J Xu, RM Kanojia, F Du… - Journal of medicinal …, 2009 - ACS Publications
N Jain, J Xu, RM Kanojia, F Du, G Jian-Zhong, E Pacia, MT Lai, A Musto, G Allan, M Reuman…
Journal of medicinal chemistry, 2009•ACS PublicationsAs part of a program aimed at the development of selective estrogen receptor modulators
(SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many
compounds showed binding affinity as low as 1.6− 200 nM, displayed antagonist behaviors
in the MCF-7 human breast adenocarcinoma cell line as well in Ishikawa cell line with IC50
values in the range 0.2− 360 nM. On the basis of the side chain substitution, various
compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7 …
(SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many
compounds showed binding affinity as low as 1.6− 200 nM, displayed antagonist behaviors
in the MCF-7 human breast adenocarcinoma cell line as well in Ishikawa cell line with IC50
values in the range 0.2− 360 nM. On the basis of the side chain substitution, various
compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7 …
As part of a program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6−200 nM, displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line as well in Ishikawa cell line with IC50 values in the range 0.2−360 nM. On the basis of the side chain substitution, various compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7-(R) and its major metabolites 5-(R) and 6-(R) were evaluated in several in vivo models of estrogen action. Relative to a full estrogen agonist (ethynyl estradiol) and the SERM raloxifene, 7-(R) was found to be a potent SERM that behaved as antagonist in the uterus and exhibited estrogen agonistic activity on bone, plasma lipids, hot flush, and vagina. The overall pharmacokinetic profile and stability were significantly improved compared to those of the phase 2 development compound 9-(R).
ACS Publications
以上显示的是最相近的搜索结果。 查看全部搜索结果